Gold(I)-thiolates: slow-acting anti-arthritic drugs

Haynes, Davin R.; Whitehouse, M. W.

doi:10.1007/978-94-009-1253-3_8

Cited by 7 publications

(1 citation statement)

References 81 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For further background on gold pharmacology, the following reviews are recommended: they do provide differing viewpoints and valuable bibliographies: Brown and Smith, 1980;Leibfarth and Persellin, 1981;Lewis and Walz, 1982;Kean, Forester et al, 1985;Haynes and Whitehouse, 1989;Kean et al, 1991;Wigley and Brooks, 1992;Graham et al, 1993;Merchant, 1998;Shaw, 1999;Eisler, 2003;Messori and Marcon, 2004).…”

Section: W Whitehousementioning

confidence: 98%

Therapeutic gold. Is it due for a come-back?

Whitehouse

2008

Inflammopharmacol

View full text Add to dashboard Cite

The historical use of metallic gold and gold complexes in medicine is briefly outlined. Currently, there is a large body of opinion that they belong to another age, are no longer relevant and that there are more-than-adequate successors to replace them. Nevertheless some challenging questions remain: (1) Should we now ignore their remarkable properties for ameliorating rheumatoid arthritis, even inducing remissions and for preventing arthritis development in animals? (i) What mechanisms underlie their clinical activity? (ii) Can some of the adverse effects of traditional therapy with gold-thiolate complexes be reduced/prevented by either modifying their formulations, or by using some of their bio-transformation products at much lower doses? (iii) Are they equivalent, perhaps even superior to biological DMARDs (anti-TNFalpha, anti-IL-1), and if so, more cost effective?

show abstract